Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status

INTRODUCTION: Retrospective studies suggest that p53 alteration is prognostic for recurrence in patients with urothelial bladder cancer and predictive for benefit from combination methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) adjuvant chemotherapy. PATIENTS AND METHODS: Patients with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Stadler, Walter M., Lerner, Seth P., Groshen, Susan, Stein, John P., Shi, Shan-Rong, Raghavan, Derek, Esrig, David, Steinberg, Gary, Wood, David, Klotz, Laurence, Hall, Craig, Skinner, Donald G., Cote, Richard J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2011
Materias:
Original Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3164246/
https://ncbi.nlm.nih.gov/pubmed/21810677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.34.4028
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares